InMode Responds To BTL Petition for Inter Partes Review Of Patent InMode Is Asserting Against BTL
- None.
- None.
Insights
In the sphere of intellectual property disputes, the action by BTL Industries to seek an Inter Partes Review (IPR) of InMode's patent is a strategic legal maneuver. The IPR process can serve as a litmus test for the robustness of a patent's claims, examining if they stand up to the scrutiny of the US Patent & Trademark Office (USPTO). It is also telling that InMode is not taken aback by this move, suggesting they might have anticipated such opposition and have confidence in their patent's enforceability.
This patent wrangle, particularly if InMode's claims are upheld, could potentially dissuade other competitors from encroaching on their intellectual turf. For stakeholders, the outcome of both the IPR and the district court litigation could have significant implications on InMode's market share and revenue streams, especially within the niche of radio-frequency based feminine rejuvenation products.
From a technological standpoint, the patent at the center of this dispute appears to cover advancements in non-invasive, radio-frequency based feminine rejuvenation treatments. This technology is central to a growing market focused on aesthetic medical treatments. InMode's strategic acquisition of this technology from Viveve and their subsequent enforcement actions underline the commercial value they attribute to it.
For investors, the long-term business outlook of InMode hinges on the ability to defend and maintain their intellectual property rights. The success in the courtroom and before the USPTO could bolster InMode's positioning as a leader in the field, potentially enhancing investor confidence and affecting the stock market valuation of the company.
When examining the financial repercussions, it's essential to understand that legal disputes like this can be a double-edged sword. On one hand, a victory for InMode could serve to protect their revenue from key products and even allow for royalty gains from licensing deals. On the other hand, litigation is costly and a protracted legal battle might weigh on the company's financials. Moreover, market sentiment could be influenced by the perceived risks associated with the ongoing litigation.
The financial markets often react to such disputes with volatility in the stock prices of the involved entities. Investors should consider the potential costs, the likelihood of success based on patent strength and any precedents of similar cases that might shed light on possible outcomes.
YOKNEAM,
InMode's Chief Technology Officer, Dr. Michael Kreindel, commented "The filing of a USPTO petition for Inter Partes review by a defendant accused of patent infringement is commonplace, and something that occurs in most important patent disputes. BTL's petition did not come as a surprise to us, and we look forward to defending the validity of our patent before the USPTO." Dr. Kreindel added "We also look forward to continuing our case against BTL in the
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Forward-Looking Statements
The information in this press release includes forward-looking statements within the meaning of the federal securities laws. These statements generally relate to future events or InMode's future financial or operating performance, including, but not limited to, the 2024 revenue projection described above. Actual outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. In some cases, you can identify these statements because they contain words such as "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "will," "would" and similar expressions that concern our expectations, strategic plans or intentions. Forward-looking statements are based on management's current expectations and assumptions, and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Consequently, actual results could differ materially from those indicated in these forward-looking statements. When considering these forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in InMode's Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 13, 2024, and our future public filings. InMode undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which pertain only as of the date of this press release.
Company Contact: Yair Malca Chief Financial Officer Phone: (949) 305-0108 Email: Yair.Malca@inmodemd.com | Investor Relations Contact: Miri Segal MS-IR LLC Phone: (917) 607-8654 Email: ir@inmodemd.com |
Logo - https://mma.prnewswire.com/media/1064477/InMode_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/inmode-responds-to-btl-petition-for-inter-partes-review-of-patent-inmode-is-asserting-against-btl-302115541.html
SOURCE InMode LTD
FAQ
What is the ticker symbol for InMode ?
What recent petition did BTL Industries, Inc. file against InMode?
What products of BTL are alleged to infringe InMode's patent?
Who commented on InMode's response to BTL's petition?
What technology did InMode acquire from Viveve?
